Phospholipase A2 as a therapeutic target for atherosclerosis

Clinical Lipidology

Volumn 5, Issue 1, 2010, Pages 43-56

  Karakas, Mahir ^a   Koenig, Wolfgang ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

Atherosclerosis; Darapladib; Inflammation; Lipoprotein associated phospholipase A2; Secretory phospholipase A2; Varespladib

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ATORVASTATIN; DARAPLADIB; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PHOSPHOLIPASE A2; PLACEBO; PRAVASTATIN; SECRETORY PHOSPHOLIPASE A2; VARESPLADIB;

ACUTE CORONARY SYNDROME; ARTERIAL PRESSURE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BIOCHEMISTRY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; DISEASE COURSE; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG POTENTIATION; ENZYME INHIBITION; GERIATRIC PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; INFLAMMATION; ISCHEMIC HEART DISEASE; LIPID METABOLISM; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; UNSPECIFIED SIDE EFFECT;

EID: 77649109228     PISSN: 17460875     EISSN: None     Source Type: Journal    
DOI: 10.2217/clp.09.74     Document Type: Review

References (106)

1. Tjoelker LW, Eberhardt C, Unger J et al.: Plasma platelet-activating factor acetylhydrolase is a secreted phospholipase A2 with a catalytic triad. J. Biol. Chem. 270, 25481-25487 (1995).
2. Wilensky RL, Macphee CH: Lipoprotein-associated phospholipase A2 and atherosclerosis. Curr. Opin. Lipidol. 20(5), 415-420 (2009).
3. Six DA, Dennis EA: The expanding superfamily of phospholipase A2 enzymes: classification and characterization. Biochim. Biophys. Acta 1488, 1-19 (2000).
4. Hakkinen T, Luoma JS, Hiltunen MO et al.: Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerosclerotic lesions. Arterioscler. Thomb. Vasc. Biol. 19, 2909-2917 (1999).
5. Carpenter KL, Dennis IF, Challis IR et al.: Inhibition of lipoprotein-associated phospholipase A2 diminishes the death-including effects of oxidized LDL on human monocyte-macrophages. FEBS Lett. 505, 357-363 (2001).
6. Namagaladze D, Preiss S, Dröse S, Brandt U, Brüne B: Phospholipase A2-modified low density lipoproteins induces mitochondrial uncoupling and lowers reactive oxygen species in phagocytes. Atherosclerosis 208(1), 142-147 (2010).
7. Stafforini DM, Tjoelker LW, McCormick SP et al.: Molecular basis of the interaction between plasma platelet-activating factor acetylhydrolase and low-density lipoprotein. J. Biol. Chem. 274, 7018-7024 (1999).
8. Macphee CH, Moores KE, Boyd HF et al.: Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochem. J. 338, 479-487 (1999).
9. Oörni K, Kovanen PT: Lipoprotein modification by secretory phospholipase A2 enzymes contributes to the initiation and progression of atherosclerosis. Curr. Opin. Lipidol. 20(5), 421-427 (2009).
10. Lähdesmäki K, Plihtari R, Soininen P et al.: Phospholipase A2-modified LDL particles retain the generated hydrolytic products and are more atherogenic at acidic pH. Atherosclerosis 207(2), 352-359 (2009).
11. Wilensky RL, Shi Y, Mohler ER 3rd et al.: Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development. Nat. Med. 14, 1059-1066 (2008).
12. Lavi S, Lavi R, McConnell JP, Lerman LO, Lerman A: Lipoprotein-associated phospholipase A2: review of its role as a marker and a potential participant in coronary endothelial dysfunction. Mol. Diagn. Ther. 11, 219-226 (2007).
13. Bäck M: Leukotriene signaling in atherosclerosis and ischemia. Cardiovasc. Drugs Ther. 23, 41-48 (2009).
14. Balsinde J, Winstead MV, Dennis EA: Phospholipase A2 regulation of arachidonic acid mobilization. FEBS Lett. 531, 2-6 (2002).
15. Kolodgie FD, Burke AP, Skorija KS et al.: Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 26, 2523-2529 (2006).
16. Macphee CH, Nelson JJ, Zalewski A: Lipoprotein-associated phospholipase A2 as a target of therapy. Curr. Opin. Lipidol. 16, 442-446 (2005).
17. Shi Y, Zhang P, Zhang L et al.: Role of lipoprotein-associated phospholipase A2 in leukocyte activation and inflammatory responses. Atherosclerosis 191, 54-62 (2007).
18. Kume N, Gimbrone MA Jr: Lysophosphatidylcholine transcriptionally induces growth factor gene expression in cultured human endothelial cells. J. Clin Invest. 93, 907-911 (1994).
19. Spangelo BL, Jarvis WD: Lysophosphatidylcholine stimulates interleukin-6 release from rat anterior pituitary cells in vitro. Endocrinology 137, 4419-4426 (1996).
20. Tsimikas S, Tsironis T, Tselepis AD: New insights into the role of lipoprotein(a)-associated phospholipase A2 in atherosclerosis and cardiovascular disease. Arterioscler. Thromb. Vasc. Biol. 27, 2094-2099 (2007).
21. Tjoelker LW, Wilder C, Eberhardt C et al.: Anti-inflammatory properties of a platelet-activating factor acetylhydrolase. Nature 374, 549-553 (1995).
22. Lerman A, McConnell JP: Lipoprotein-associated phospholipase A2: a risk marker or a risk factor? Am. J. Cardiol. 101, 11F-22F (2008).
23. Theilmeier G, De Geest B, Van Veldhofen PP et al.: HDL-associated PAF-AH reduces endothelial adhesiveness in apoE-/-mice. FASEB J. 14, 2032-2039 (2000).
24. Chen CH, Jiang T, Yang JH et al.: Low-density lipoprotein in hypercholesterolemic human plasma induces vascular endothelial cell apoptosis by inhibiting fibroblast growth factor 2 transcription. Circulation 107, 2102-2108 (2003).
25. Hurt-Camejo E, Camejo G, Peilot H, Oori K, Kovanen P: Phospholipase A2 in vascular disease. Circ. Res. 89, 298-304 (2001).
26. Hurt-Camejo E, Andersen S, Standal R et al.: Localisation of nonpancreatic secretory phospholipase A2 in normal and atherosclerotic arteries-activity of the isolated enzyme on low-density lipoproteins. Arterioscler. Thromb. Vasc. Biol. 17, 300-309 (1997).
27. Kimura-Matsumoto M, Ishikawa Y, Komiyama K et al.: Expression of secretory phospholipase A2s in human atherosclerosis development. Atherosclerosis 196, 81-91 (2008).
28. Bostrom MA, Boyanovsky BB, Jordan CT et al.: Group V secretory phospholipase A2 promotes atherosclerosis: evidence from genetically altered mice. Arterioscler. Thromb. Vasc. Biol. 27, 600-606 (2007).
29. Pfeilschifter J, Shalkwijk C, Briner VA, van den Bosch H: Cytokine-stimulated secretion of group-II phospholipase-A2 by rat mesangial cells-its contribution to arachidonic acid release and prostaglandin synthesis by cultured rat glomerular cells. J. Clin. Invest. 92, 2516-2523 (1993).
30. Pettersson C, Fogelstrand L, Rosengren B et al.: Increased lipolysis by secretory phospholipase A2 group V of lipoproteins in diabetic dyslipidaemia. J. Intern. Med. 264, 155-165 (2008).
31. Anderson KM, Roshak A, Winkler JD, McCord M, Marshall LA: Cytosolic 85-kDa phospholipase A2-mediated release of arachidonic acid is critical for proliferation of vascular smooth muscle cells. J. Biol. Chem. 272, 30504-30511 (1998).
32. Karabina SA, Brocheriou I, Le Naour G et al.: Atherogenic properties of LDL particles modified by human group X secreted phospholipase A2 on human endothelial cell function. FASEB J. 20, 2547-2549 (2006).
33. Lambeau G, Gelb MH: Biochemistry and physiology of mammalian secreted phospholipases A2. Annu. Rev. Biochem. 77, 495-520 (2008).
34. Kleinman Y, Krul ES, Burnes M, Aronson W, Pfleger B, Schonfeld G: Lipolysis of LDL with phospholipase A2 alters the expression of selected ApoB-100 epitopes and the interaction of LDL with cells. J. Lipid Res. 29, 729-743 (1988).
35. Hakala JK, Oorni K, Pentikainen MO, Hurt-Camejo E, Kovanen PT: Lipolysis of LDL by human secretory phospholipase A2 induces particle fusion and enhances the retention of LDL to human aortic proteoglycans. Arterioscler. Thromb. Vasc. Biol. 21, 1053-1058 (2001).
36. Flood C, Gustafsson M, Pitas RE, Arnaboldi L, Walzem RL, Boren J: Molecular mechanism for changes in proteoglycan binding on compositional changes of the core and the surface of low-density lipoprotein-containing human apolipoprotein B100. Arterioscler. Throm. Vasc. Biol. 24, 564-570 (2004).
37. Sartipy P, Camejo G, Svensson L, Hurt-Camejo E: Phospholipase A2 modification of low density lipoproteins forms small high density particles with increased affinity for proteoglycans and glycosaminoglycans. J. Biol. Chem. 274, 25913-25920 (1999).
38. Boyanovsky BB, van der Westhuyzen DR, Webb NR: Group V secretory phospholipase A2-modified low density lipoprotein promotes foam cell formation by a SR-A-and CD36-independent process that involves cellular proteoglycans. J. Biol. Chem. 280, 32746-32752 (2005).
39. Boyanovsky BB, Shridas P, Simons M et al.: Syndecan-4 mediates macrophage uptake of group V secretory phospholipase A2-modified LDL. J. Lipid Res. 50, 641-650 (2008).
40. Rosengren B, Peilot H, Umaerus M et al.: Secretory phospholipase A2 group V: lesion distribution, activation by arterial proteoglycans, and induction in aorta by western diet. Arterioscler. Thromb. Vasc. Biol. 26, 1579-1585 (2006).
41. Maor I, Hayek T, Hirsh M, Iancu TC, Aviram M: Macrophage-released proteoglycans enhance LDL aggregation: studies in aorta from apolipoprotein E-deficient mice. Atherosclerosis 150, 91-101 (2000).
42. Antonsen MW, Stengel D, Hourton D, Ninio E, Johansen B: Mildly oxidized LDL induces expression of group IIa secretory phospholipase A2 in human monocyte-derived macrophages. Arterioscler. Thromb. Vasc. Biol. 20, 1276-1282 (2000).
43. Hanasaki K, Yamada K, Yamamoto S et al.: Potent modification of low density lipoprotein by group X secretory phospholipase A2 is linked to macrophage foam cell formation. J. Biol. Chem. 277, 29116-29124 (2002).
44. Tietge UJ, Pratico D, Ding T et al.: Macrophage-specific expression of group IIA sPLA2 results in accelerated atherogenesis by increasing oxidative stress. J. Lipid Res. 46, 1604-1616 (2005).
45. Watson AD, Leitinger N, Navab M et al.: Structural identification by mass spectrometry of oxidized phospholipids in minimally oxidized low density lipoproteins that induce monocyte/endothelial interactions and evidence for their presence in vivo. J. Biol. Chem. 272, 13597-13603 (1997).
46. Hansson GK: Mechanisms of disease-inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 352, 1685-1695 (2005).
47. Jonsson-Rylander AC, Lundin S, Rosengren B, Pettersson C, Hurt-Camejo E: Role of secretory phospholipases in artherogenesis. Curr. Atheroscler. Rep. 10, 252-259 (2008).
48. Zalewski A, Macphee C: Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target. Arterioscler. Thromb. Vasc. Biol. 25, 923-931 (2005). (Pubitemid 40627835)
49. Andreani M, Olivier JL, Berenbaum F, Raymondjean M, Bereziat G: Transcriptional regulation of inflammatory secreted phospholipases A2. Biochim. Biophys. Acta Mol. Cell Biol. Lipids 1488, 149-158 (2000).
50. Peilot H, Rosengren B, Bondjers G, Hurt-Camejo E: Interferon-g induces secretory group IIA phospholipase A2 in human arterial smooth muscle cells-involvement of cell differentiation, STAT-3 activation, and modulation by other cytokines. J. Biol. Chem. 275, 22895-22904 (2000).
51. Menschikowski M, Hempel U, Dinnebier G, Lattke P, Wenzel KW, Jaros W: Changes in epitope exposition of apolipoprotein A-I on the surface of high density lipoproteins after phospholipase A2 treatment. Atherosclerosis 117, 159-167 (1995).
52. Tietge UJ, Maugeais C, Cain W et al.: Overexpression of secretory phospholipase A2 causes rapid catabolism and altered tissue uptake of high density lipoprotein cholesteryl ester and apolipoprotein A-I. J. Biol. Chem. 275, 10077-10084 (2000).
53. Murakami M, Kudo I: New phospholipase A2 isozymes with a potential role in atherosclerosis. Curr. Opin. Lipidol. 14, 431-436 (2003).
54. Ishimoto Y, Yamada K, Yamamoto S, Ono T, Notoya M, Hanasaki K: Group V and X secretory phospholipase A2s-induced modification of high-density lipoprotein linked to the reduction of its anti-atherogenic functions. Biochim. Biophys. Acta 1642, 129-138 (2003).
55. Ivandic B, Castellani LW, Wang XP et al.: Role of group II secretory phospholipase A2 in atherosclerosis: 1. Increased atherogenesis and altered lipoproteins in transgenic mice expressing group IIA phospholipase A2. Arterioscler. Thromb. Vasc. Biol. 19, 1284-1290 (1999).
56. Webb NR, Bostrom MA, Szilvassy SJ et al.: Macrophage-expressed group IIA secretory phospholipase A2 increases atherosclerotic lesion formation in LDL receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol. 23, 263-268 (2003).
57. Ghesquiere SA, Gijbels MJ, Anthonsen M et al.: Macrophage-specific overexpression of group IIA sPLA2 increases atherosclerosis and enhances collagen deposition. J. Lipid Res. 46, 201-210 (2005).
58. Koenig W, Khuseyinova N: Lipoprotein-associated and secretory phospholipase A2 in cardiovascular disease: the epidemiologic evidence. Cardiovasc. Drugs Ther. 23, 85-92 (2009).
59. Corson MA, Jones PH, Davidson MH: Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker. Am. J. Cardiol. 101, S41-S50 (2008).
60. Garza CA, Montori VM, McConnell JP, Somers VK, Kullo IJ, Lopez-Jimenez F: Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: a systematic review. Mayo Clin. Proc. 82, 159-165 (2007).
61. Packard CJ, O'Reilly DS, Caslake MJ et al.: Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med. 343, 1148-1155 (2000).
62. Blake GJ, Dada N, Fox JC, Manson JE, Ridker PM: A prospective evaluation of lipoprotein-associated phospholipase A2 levels and the risk of future cardiovascular events in women. J. Am. Coll. Cardiol. 38, 1302-1306 (2001).
63. Ballantyne CM, Hoogeveen RC, Bang H et al.: Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation 109, 837-842 (2004).
64. Koenig W, Khuseyinova N, Lowel H, Trischler G, Meisinger C: Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany. Circulation 110, 1903-1908 (2004).
65. Oei HH, van der Meer IM, Hofman A et al.: Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. Circulation 111, 570-575 (2005).
66. Kiechl S, Willeit J, Mayr M et al.: Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study. Arterioscler. Thromb. Vasc. Biol. 27, 1788-1795 (2007).
67. Daniels LB, Laughlin GA, Sarno MJ, Bettencourt R, Wolfert RL, Barrett-Connor E: Lipoprotein-associated phospholipase A2 is an independent predictor of incident coronary heart disease in an apparently healthy older population: the Rancho Bernardo Study. J. Am. Coll. Cardiol. 51, 913-919 (2008).
68. Jenny NS, Solomon C, Cushman M et al.: Lipoprotein-associated phospholipase A2 and cardiovascular disease: results from the Cardiovascular Health Study. Circulation 113, E332; Abstract (2006).
69. Caslake MJ, Cooney J, Murray E et al.: Lipoprotein-associated phospholipase A2 as a risk factor for coronary vascular disease in the elderly. Atherosclerosis. Suppl. 7, 484; Abstract (2006).
70. O'Donoghue M, Morrow DA, Sabatine MS et al.: Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial. Circulation 113, 1745-1752 (2006).
71. Oldgren J, James SK, Siegbahn A, Wallentin L: Lipoprotein-associated phospholipase A2 does not predict mortality or new ischaemic events in acute coronary syndrome patients. Eur. Heart J. 28, 699-704 (2007).
72. Gerber Y, McConnell JP, Jaffe AS, Weston SA, Killian JM, Roger VL: Lipoprotein-associated phospholipase A2 and prognosis after myocardial infarction in the community. Arterioscler. Thromb. Vasc. Biol. 26, 2517-2522 (2006). (Pubitemid 44607474)
73. Möckel M, Müller R, Vollert JO et al.: Lipoprotein-associated phospholipase A2 for early risk stratification in patients with suspected acute coronary syndrome: a multi-marker approach: the North Wuerttemberg and Berlin Infarction Study-II (NOBIS-II). Clin. Res. Cardiol. 96, 604-612 (2007).
74. Brilakis ES, McConnell JP, Lennon RJ, Elesber AA, Meyer JG, Berger PB: Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. Eur. Heart J. 26, 137-144 (2004).
75. Koenig W, Twardella D, Brenner H, Rothenbacher D: Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function and hemodynamic stress. Arterioscler. Thromb. Vasc. Biol. 26, 1586-1593 (2006).
76. Corsetti JP, Rainwater DL, Moss AJ, Zareba W, Sparks CE: High lipoprotein-associated phospholipase A2 is a risk factor for recurrent coronary events in postinfarction patients. Clin. Chem. 52, 1331-1338 (2006).
77. Sabatine MS, Morrow DA, O'Donoghue M et al.; PEACE Investigators: Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 27, 2463-2469 (2007).
78. Winkler K, Hoffmann MM, Winkelmann BR et al.: Lipoprotein-associated phospholipase A2 predicts 5-year cardiac mortality independently of established risk factors and adds prognostic information in patients with low and medium high-sensitivity C-reactive protein (the Ludwigshafen Risk and Cardiovascular Health Study). Clin. Chem. 53, 1440-1447 (2007).
79. Anthonsen MW, Stengel D, Hourton D, Ninio E, Johansen B: Mildly oxidized LDL induces expression of group IIa secretory phospholipas A2 in human monocyte-derived macrophages. Arterioscler. Thromb. Vasc. Biol. 20, 1276-1282 (2000).
80. Grönroos JO, Salonen JH, Viander M, Nevalainen TJ, Laine VJ: Roles of group IIA phospholipase A2 and complement in killing of bacteria by acute phase serum. Scand. J. Immunol. 62, 413-419 (2005).
81. Möckel M, Danne O, Müller R et al.: Development of an optimized multimarker strategy for early risk assessment of patients with acute coronary syndromes. Clin. Chim. Acta 393, 103-109 (2008).
82. Hack CE , Wolbink GJ, Schalkwijk C, Speijer H, Hermens WT, van den Bosch H: A role for secretory phospholipase A2 and C-reactive protein in the removal of injured cells. Immunol. Today 18, 111-115 (1997).
83. Jaross W, Eckey R, Menschikowski M: Biological effects of secretory phospholipase A2 group IIA on lipoproteins and in atherogenesis. Eur. J. Clin. Invest. 32, 383-393 (2002).
84. Boekholdt SM, Keller TT, Wareham NJ et al.: Serum levels of type II secretory phospholipase A2 and the risk of future coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study. Arterioscler. Thromb. Vasc. Biol. 25, 839-846 (2005).
85. Mallat Z, Benessiano J, Simon T et al.: Circulating secretory phospholipase A2 activity and risk of incident coronary events in healthy men and women. The EPIC-Norfolk Study. Arterioscler. Thromb. Vasc. Biol. 27, 1177-1183 (2007).
86. Mallat Z, Steg PG, Benessiano J et al.: Circulating secretory phospholipase A2 activity predicts recurrent events in patients with severe acute coronary syndromes. J. Am. Coll. Cardiol. 46, 1249-1257 (2005).
87. Kugiyama K, Ota Y, Sugiyama S et al.: Prognostic value of plasma levels of secretory type II phospholipase A2 in patients with unstable angina pectoris. Am. J. Cardiol. 86, 718-722 (2000). (Pubitemid 30734924)
88. Hartford M, Wiklund O, Mattsson Hulten L et al.: CRP, interleukin-6, secretory phospholipase A2 group IIA, and intercellular adhesion molecule-1 during the early phase of acute coronary syndromes and long-term follow-up. Int. J. Cardiol. 108, 55-62 (2006).
89. Kugiyama K, Ota Y, Takazoe K et al.: Circulating levels of secretory type II phospholipase A2 predict coronary events in patients with coronary artery disease. Circulation 100, 1280-1284 (1999). (Pubitemid 29440119)
90. Liu PY, Li YH, Tsai WC et al.: Prognostic value and the changes of plasma levels of secretory type II phospholipase A2 in patients with coronary artery disease undergoing percutaneous coronary intervention. Eur. Heart J. 24, 1824-1832 (2003).
91. Koenig W, Vossen CY, Mallat Z, Brenner H, Benessiano J, Rothenbacher D: Association between type II secretory phospholipase A2 plasma concentrations and activity and cardiovascular events in patients with coronary heart disease. Eur. Heart J. 30(22), 2742-2748 (2009).
92. Rosenson RS: Future role for selective phospolipase A2 inhibitors in the prevention of atherosclerotic cardiovascular disease. Cardiovasc. Drugs Ther. 23, 93-101 (2009).
93. Wilensky RL, Shi Y, Zalewski A et al.: A selective inhibitor of Lp-PLA2, reduces coronary atherosclerosis in diabetic, hypercholesterolemic swine. Presented at: American Heart Association Scientific Sessions. Orlando, FL, USA, 4-7 November 2007.
94. Johnson A, Zalewski A, Janmohamed S et al.: Lipoprotein-associated phospholipase A2 (Lp-PLA2) activity, an emerging CV risk marker, can be inhibited in atherosclerotic lesions and plasma by novel pharmacologic intervention: the results of a multicenter clinical study. Circulation 110, III-590 (2004).
95. Mohler ER, Ballantyne CM, Davidson MH et al.: The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study. J. Am. Coll. Cardiol. 51, 1632-1641 (2008).
96. Serruys PW, Garcia-Garcia HM, Buszman P et al.: Effects of the direct lipoprotein-associated phospholipase A2 inhibitor darapladib on human coronary atherosclerotic plaque. Circulation 118, 1171-1180 (2008).
97. McCullough PA: Darapladib and atherosclerotic plaque: should lipoprotein-associated phospholipase A2 be a therapeutic target? Curr. Atheroscler. Rep. 11, 334-337 (2009).
98. Karakas M, Koenig W: Varespladib methyl, an oral phospholipase A2 inhibitor for the potential treatment of coronary artery disease. IDrugs 12(9), 585-592 (2009).
99. Fraser H, Hislop C, Christie RM et al.: Varespladib (A-002), a secretory phospholipase A2 inhibitor, reduces atherosclerosis and aneurysm formation in apoE-/-mice. J. Cardiovasc. Pharmacol. 53, 60-65 (2009).
100. Shaposhnik Z, Wang X, Trias J, Fraser H, Lusis AJ: The synergistic inhibition of atherogenesis in ApoE-/-mice between pravastatin and the sPLA2 inhibitor varespladib (A-002). J. Lipid Res. 50, 623-629 (2009).
101. Leite JO, Vaishnav U, Puglisi M, Fraser H, Trias J, Fernandez ML: A-002 (varespladib), a phospholipase A2 inhibitor, reduces atherosclerosis in guinea pigs. BMC Cardiovasc. Disord. 9, 1-9 (2009).
102. Kennedy BP, Payette P, Mudgett J et al.: A natural disruption of the secretory group II phospholipase A2 gene in inbred mouse strains. J. Biol. Chem. 270, 22378-22385 (1995).
103. Rosenson RS, Hislop C, McConnell D et al.: Effects of 1H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): a Phase II double-blind, randomized, placebo-controlled trial. Lancet 373, 649-658 (2009).
104. Rosenson RS, Hislop C, Elliott M, Stasiv Y: Effects of a selective inhibitor of secretory phospholipase A2 on low density and very low density lipoprotein subclasses in stable coronary heart disease patients. Presented at: American Heart Association Scientific Sessions. New Orleans, LA, USA, 8-12 November 2008.
105. Libby P: The forgotten majority: unfinished business in cardiovascular risk reduction. J. Am. Coll. Cardiol. 46, 1225-1228 (2005).
106. Anthera Pharmaceuticals Inc. (CA, USA) www.anthera.com